Wacker Biotech is a dedicated contract manufacturer of biopharmaceuticals with over 20 years of experience in microbial systems. Our customers benefit from a comprehensive service for the development of robust and highly efficient production processes and GMP-compliant manufacturing for clinical trials and commercial supply.

Service

Wacker Biotech’s services cover the whole process chain: from construction and optimization of host/vector systems to delivery of the bulk API. A well-equipped quality control department supports characterization of master and working cell banks and development of fermentation and downstream processing as well as GMP-manufacturing. Apart from routine lot-release testing, the quality control department also performs ICH-compliant stability studies. For more flexibility, we can develop the entire production process and analytical methods or transfer projects at each stage.

Efficient purification processes are the result of systematic selection of chromatography media, specification of chromatography parameters in direct liaison with the process development analytical team, and our employees’ experience. ()

Projects are managed by dedicated project managers assigned to each project. They coordinate cross-departmental project teams and ensure that the project is executed as planned. These project managers are the customers’ primary points of contact.

Manufacturing

Wacker Biotech operates a GMP multiproduct facility in Jena, Germany:

Cost-Saving Proprietary Technologies

To enrich its contract biomanufacturing activities, Wacker Biotech also offers technologies that reduce the overall cost of goods and help developing novel biopharmaceuticals.

The innovative and highly efficient ESETEC^® Escherichia coli expression technology results in high-yield secretion of recombinant proteins in native conformation into the culture broth. With ESETEC^®, several low-yield process steps (e.g., refolding) are no longer necessary, so downstream processing becomes much easier and more cost effective.

Wacker Biotech also holds IP rights for DENSETEC^®, a high-cell density fermentation technology. DENSETEC^® allows optimal volumetric productivity in robust and highly reproducible fermentation regimes. Product yields >10 g/L have already been reached.

PASylation^® is an innovative technology from the German company XL-protein GmbH, which enables the development of biopharmaceuticals with extended plasma half-life. WACKER offers access to this technology for the production of PASylated proteins using the ESETEC^® secretion system. For PASylated Fabs, yields of 4.3 g/L have been achieved with ESETEC^®.

Regulatory Affairs and Track Record

Our quality assurance system is based on the ICH Guidelines and European and US regulatory requirements and has been approved in numerous inspections by authorities and in client audits. Wacker Biotech holds a manufacturing license for the production of recombinant proteins and has experience with a large number of pharmaceutical and biotechnology companies located in Europe and the United States. Wacker Biotech has a strong track record and experience from clinical phase 1 to phase 3.

About the Author

Author Details
Dr. Silvana Di Cesare is Business Development Manager at Wacker Biotech GmbH, Hans Knoell Str. 3, 07743 Jena, Germany; silvana. [email protected], www.wacker.com/biologics.